Cor.Con. International

CPHI Pharma Awards 2026

Epilamba Junior shortlisted for the CPHI Pharma Awards 2026

International Road Map 2026

What a 2026 for Cor.Con. International and its International Road Map!

Co-morbidities in epilepsy, the impact on children’s lives

Comorbidities in childhood epilepsy are numerous and complex. The co-morbidities of epilepsy do not only affect the cognitive and emotional spheres, but also have a direct impact on the child’s quality of life and global development.

Epilamba Junior

Epilamba Junior is a food supplement for the management of comorbidities in anti-epileptic drug therapy. Effective on brain and gastrointestinal functions.

Homocysteine

High homocysteine: what it is, why it happens and how to lower it

Cogiton

Cogiton is a patented food supplement based on a specific
and harmonized combination of ingredients
sustaining the normal function of the nervous system

Menopause

Menopause: what it is, how to recognise the initial signs and relief from symptoms

Afragil

Afragil is a food supplement for the gynecological health. Effective on oxidative stress and menopause symptoms

Company

We are a private Italian company that daily researches and develops innovative solutions to wellness problems. We believe that people can live longer and healthier lives.

Learn more

Products

We develop evidence-based food supplements and cosmeceuticals, from scientific rationale to market, through research, scientific publications, patenting and production.

Learn more

Services

We work at your side in order to create original health-oriented products with innovative and customized formulas, dictated by market and by your requirements.

Learn more

Product Highlight

Acustop

Acustop is a clinically tested supplement developed to support the inner ear functions. Its unique formulation, based on the functional synergy between vitamins, antioxidants, and neuroprotective compounds, helps to preserve hearing functions.

  • Supports vascular functions, help to maintain inner ear wellbeing in cases of reduced cochlear hypoperfusion.
  • Improves the quality of life of people suffering from hearing dysfunctions, as shown in clinical study.
  • Clinically tested. Relief as early as 4 weeks.

News and Articles

Cor.Con. International at PharmaSynergyOTC 2026 in Rome

The event provided an excellent opportunity to meet current and potential partners, explore new business opportunities and discuss future collaborations across international markets.

As Cor.Con. International continues to expand its international footprint, face-to-face meetings remain an important part of our approach to building strong, long-term partnerships and developing new opportunities in the healthcare sector.

Bridging Industry and Academia: Cor.Con. International Delivers Lecture on Food Supplement Development at the University of Parma

Cor.Con. International had the pleasure of contributing to a lecture at the University of Parma entitled “From Idea to Market: How to Develop a Food Supplement.”

We believe that interaction between industry, universities, and local institutions plays an essential role in helping students bridge the gap between academic knowledge and real-world applications.

Epilamba Junior shortlisted for the CPHI Pharma Awards 2026

Epilamba Junior by Cor.Con. International has been shortlisted as a finalist for the CPHI Pharma Awards 2026 in the Finished Formulation category.

Read the article
Logos